Kyverna Therapeutics, Inc. (KYTX)
NASDAQ:KYTX
Want to see KYTX full AI Analyst Report?
KYTX Stock Chart & Stats
$9.93
-$0.14(-3.63%)
At close: 4:00 PM EST
$9.93
-$0.14(-3.63%)
Day’s Range― - ―
52-Week Range$2.52 - $13.67
Previous CloseN/A
Volume87.17K
Average Volume (3M)846.70K
Market Cap
$478.46M
Enterprise Value$349.85M
Total Cash (Recent Filing)$236.45M
Total Debt (Recent Filing)$8.94M
Price to Earnings (P/E)―
Beta1.76
Next Earnings
Aug 18, 2026EPS Estimate
-0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.28
Shares Outstanding60,795,210
10 Day Avg. Volume771,054
30 Day Avg. Volume846,695
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)1.79
Price to Sales (P/S)0.00
P/FCF Ratio-2.71
Enterprise Value/Market Cap0.73
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-403.99
Enterprise Value/Ebitda-2.28
Forecast
1Y Price Target
$30.00Price Target Upside202.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.87
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Registrational Clinical Efficacy (miv-cel)Registrational KYSA-8 results showing statistically significant, durable benefit and discontinuation of chronic immunotherapies indicate miv‑cel may achieve first approval in a high‑unmet‑need indication. A first‑in‑class approval would create a lasting commercial foothold and durable competitive advantage in neuroimmunology.
Favorable Safety & Outpatient PotentialReported absence of high‑grade CRS/neurotoxicity and manageable hematologic events supports outpatient administration. Safer, outpatient-capable CAR T reduces delivery complexity and costs, eases adoption by clinicians and payers, and materially improves the therapy's long‑term commercial and operational scalability.
Experienced Financial Leadership AddedAppointment of a veteran biopharma CFO to lead financial strategy, capital allocation and investor relations strengthens execution capability during the commercial transition. Seasoned finance leadership improves fundraising planning and capital discipline—key durable factors for managing biotech scale‑up risk.
Bears Say
No Revenue And Widening Net LossesZero revenue and a material widening of net losses signal the company remains pre‑commercial and dependent on clinical progress and external funding. Sustained losses increase financing needs, raise dilution risk, and mean operational viability depends on successful regulatory outcomes and execution over many quarters.
Large And Persistent Cash BurnVery large negative operating and free cash flow indicate accelerating burn with limited internal generation. Persistent high cash burn shortens runway absent new financing, constrains R&D and commercial investments, and elevates execution risk as management balances funding needs with development timelines.
Negative Returns And Eroding Equity CushionDeeply negative returns on equity and a declining equity base reflect cumulative losses eroding the company's financial cushion. This reduces flexibility to absorb setbacks, increases dependence on capital markets, and raises the probability of dilutive financings that can impair long‑term shareholder value if clinical milestones are delayed.
Kyverna Therapeutics, Inc. News
KYTX FAQ
What was Kyverna Therapeutics, Inc.’s price range in the past 12 months?
Kyverna Therapeutics, Inc. lowest stock price was $2.52 and its highest was $13.67 in the past 12 months.
What is Kyverna Therapeutics, Inc.’s market cap?
Kyverna Therapeutics, Inc.’s market cap is $478.46M.
When is Kyverna Therapeutics, Inc.’s upcoming earnings report date?
Kyverna Therapeutics, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 67 days.
How were Kyverna Therapeutics, Inc.’s earnings last quarter?
Kyverna Therapeutics, Inc. released its earnings results on May 12, 2026. The company reported -$0.66 earnings per share for the quarter, beating the consensus estimate of -$0.752 by $0.092.
Is Kyverna Therapeutics, Inc. overvalued?
According to Wall Street analysts Kyverna Therapeutics, Inc.’s price is currently Undervalued.
Does Kyverna Therapeutics, Inc. pay dividends?
Kyverna Therapeutics, Inc. does not currently pay dividends.
What is Kyverna Therapeutics, Inc.’s EPS estimate?
Kyverna Therapeutics, Inc.’s EPS estimate is -0.68.
How many shares outstanding does Kyverna Therapeutics, Inc. have?
Kyverna Therapeutics, Inc. has 60,795,210 shares outstanding.
What happened to Kyverna Therapeutics, Inc.’s price movement after its last earnings report?
Kyverna Therapeutics, Inc. reported an EPS of -$0.66 in its last earnings report, beating expectations of -$0.752. Following the earnings report the stock price went up 5.376%.
Which hedge fund is a major shareholder of Kyverna Therapeutics, Inc.?
Currently, no hedge funds are holding shares in KYTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kyverna Therapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.00 (202.11% Upside)
$30.00 (202.11% Upside)
Blogger Sentiment
Bullish
KYTX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
137.76%
12-Months-Change
Fundamentals
Return on Equity
-81.87%
Trailing 12-Months
Asset Growth
-1.39%
Trailing 12-Months
Company Description
Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical enterprise specializing in the advancement of cell-based therapies to treat individuals suffering from autoimmune disorders. Its primary experimental therapy, KYV-101, an autologous CD19 CAR T-cell candidate, is currently undergoing Phase I clinical evaluation for lupus nephritis and systemic sclerosis, and has progressed to Phase II studies for myasthenia gravis and multiple sclerosis. Furthermore, the company's pipeline includes KYV-201, an allogeneic CD19 CAR T-cell candidate still in preclinical development, designed to address a variety of autoimmune conditions. Kyverna is also exploring therapeutic solutions for other autoimmune diseases, such as inflammatory bowel disease, encompassing Crohn's disease and ulcerative colitis. The firm has established strategic alliances, including a licensing and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product, and a partnership with Kite for programs aimed at treating, diagnosing, and preventing autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. Incorporated in 2018 and headquartered in Emeryville, California, Kyverna Therapeutics, Inc. was formerly known as BAIT Therapeutics, Inc. until its name change in October 2019.
KYTX Stock 12 Month Forecast
Average Price Target
$30.00
▲(202.11% Upside)
Technical Analysis
Codexis
―
Heron Therapeutics
―
Silence Therapeutics
―
Atea Pharmaceuticals
―
Entrada Therapeutics Inc
―
Ownership Overview
23.23% Insiders
5.77% Mutual Funds
33.70% Other Institutional Investors
32.67% Public Companies and Individual Investors